Motixafortide
What the Research Actually Shows
Human: 3 studies, 3 groups · Animal: 0 · In Vitro: 0
The CXCR4-blocking peptide that mobilizes stem cells and may unlock immune access to cold tumors — from a positive Phase III to the frontier of cancer immunotherapy
EDUCATIONAL NOTICE: Peptidings exists to make peptide research accessible and honest — not to tell you what to take. The information on this site is for educational and research purposes only. It is not medical advice, and no material here is intended to diagnose, treat, cure, or prevent any disease or health condition. Consult a qualified healthcare provider before making any decisions about peptide use.
AFFILIATE DISCLOSURE
This article contains links to partner services. We may earn a commission if you purchase through them, at no cost to you. This never influences our evidence assessments or editorial content. Full policy →
BLUF: Bottom Line Up Front
Motixafortide is an experimental peptide drug being tested for two different uses in cancer treatment. The first use is straightforward: it helps release stem cells from bone marrow into the blood so they can be collected for bone marrow transplants. A Phase 3 trial proved this works — 92.5% of patients on motixafortide met the target, versus 26.2% on placebo. The second use is more ambitious: using the same mechanism to help the immune system infiltrate tumors that are normally invisible to immune cells. Early data in pancreatic cancer — one of the hardest-to-treat cancers — showed immune cells entering tumors after motixafortide treatment. The drug is not yet approved, but it has positive clinical trial data behind both of its key uses.
Motixafortide is a synthetic cyclic peptide that blocks a receptor called CXCR4 — a chemokine receptor that acts as a molecular anchor, keeping stem cells locked in the bone marrow and immune cells locked out of tumors. By disrupting this anchor, motixafortide has two distinct clinical applications: rapid mobilization of stem cells for transplantation, and potential sensitization of immune-resistant tumors to immunotherapy.
The stem cell mobilization story has already delivered a definitive result. The GENESIS Phase III trial (N=122) demonstrated that motixafortide plus G-CSF enabled 92.5% of multiple myeloma patients to meet the stem cell collection target within two apheresis sessions, compared to 26.2% with G-CSF alone (PMID 36455208). Motixafortide competes with plerixafor (Mozobil) — the only approved CXCR4 antagonist — with potentially higher affinity and faster onset.
The immunotherapy angle is earlier-stage but potentially more consequential. The COMBAT Phase 2a trial (N=37) tested motixafortide combined with pembrolizumab in metastatic pancreatic cancer — a tumor type notorious for its resistance to checkpoint immunotherapy. Biomarker data showed increased CD8+ T-cell infiltration into tumors after treatment, with a disease control rate of 77% in the combination chemotherapy cohort (PMID 32451495). If CXCR4 blockade can reliably convert "cold" tumors to "hot" ones, the implications extend far beyond pancreatic cancer.
Motixafortide represents a fundamentally different peptide oncology strategy than the somatostatin analogs in the Cancer and Oncology cluster. Where octreotide, lanreotide, and Lutathera target tumor cells directly through SSTR2, motixafortide targets the tumor microenvironment — it doesn't kill cancer cells, it removes the barriers that prevent the immune system from reaching them.
In This Article
Quick Facts: Motixafortide at a Glance
Type
Synthetic cyclic peptide CXCR4 antagonist (14 amino acids)
Also Known As
BL-8040, BKT140, motixafortide acetate
Generic Name
Motixafortide
Brand Name
None (investigational — not yet approved)
Related Compounds
Plerixafor/Mozobil (approved small-molecule CXCR4 antagonist — motixafortide's direct competitor), AMD3100 (plerixafor's research designation)
WADA Status
Not on WADA Prohibited Lists
Molecular Weight
~1,632 Da
Peptide Sequence
14-amino-acid cyclic peptide (proprietary BioLineRx sequence)
Endogenous Origin
No direct endogenous counterpart. Targets CXCR4, a chemokine receptor whose natural ligand is CXCL12 (SDF-1)
Primary Molecular Function
High-affinity CXCR4 antagonist — disrupts CXCL12/CXCR4 signaling axis → releases stem cells from bone marrow, enables immune cell infiltration into tumors
Active Fragment
Full 14-amino-acid cyclic structure required for high-affinity CXCR4 binding (~20–40× higher affinity than plerixafor)
Half-Life
Rapid onset: peak CD34+ mobilization at 6–8 hours post-injection. Pharmacodynamic effect outlasts plasma half-life
Clinical Programs
GENESIS Phase III (stem cell mobilization, complete), COMBAT Phase 2a (pancreatic cancer + pembrolizumab, complete), NDA-enabling activities ongoing
Route
Subcutaneous injection
Community Interest
Not available from peptide vendors. Investigational compound available only through clinical trials and BioLineRx access programs
FDA Status
Not approved. Phase III complete (GENESIS). NDA-enabling activities in progress for stem cell mobilization indication
Evidence Tier
2 Clinical Trials
Verdict
Reasonable Bet
The research moves fast. We read all of it so you don’t have to.
New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.
Subscribe to Peptidings WeeklyWhat Is Motixafortide?
Pronunciation: moh-TIX-ah-FOR-tide
The immune system should be able to kill cancer. T cells are exquisitely designed to recognize abnormal cells, bind to them, and destroy them. For many cancers, the problem isn't that the immune system can't fight — it's that the immune system can't get in.
Some tumors build a molecular moat around themselves. They express high levels of CXCL12 (also called SDF-1) — a chemokine signal that binds to the CXCR4 receptor on immune cells and tells them, in effect, "stay away." This creates what oncologists call an "immune-excluded" or "cold" tumor microenvironment: the cancer sits behind a chemical wall that keeps T cells on the outside looking in. Checkpoint inhibitors like pembrolizumab — drugs that release the brakes on T-cell killing — fail against cold tumors because there are no T cells in the tumor to un-brake.
Motixafortide is a 14-amino-acid cyclic peptide designed to tear down that wall. It blocks CXCR4 with 20 to 40 times higher affinity than plerixafor (the only approved CXCR4 antagonist), disrupting the CXCL12/CXCR4 signaling axis. Without that signal, stem cells are released from bone marrow into the blood (useful for transplantation), and immune cells can infiltrate tumors that were previously excluded (useful for cancer immunotherapy).
PLAIN ENGLISH
Some tumors hide from the immune system by putting up a chemical "keep out" sign. Motixafortide blocks the receptor that reads that sign, allowing immune cells to enter the tumor and attack it. The same mechanism also releases stem cells from bone marrow into the blood, which is useful for patients who need bone marrow transplants.
Origins and Discovery
Motixafortide was developed by BioLineRx, an Israeli biopharmaceutical company focused on oncology and hematology. The compound (originally designated BKT140, later BL-8040) emerged from a systematic effort to create peptide CXCR4 antagonists with higher binding affinity and longer pharmacodynamic effect than the existing small-molecule inhibitor plerixafor.
Plerixafor (AMD3100, marketed as Mozobil by Sanofi/Genzyme) was approved in 2008 for stem cell mobilization in combination with G-CSF. While effective, plerixafor has limitations — its CXCR4 binding affinity is moderate, and its mobilization kinetics require precise timing. BioLineRx designed motixafortide as a cyclic peptide that exploits the larger binding interface available to peptides versus small molecules, achieving substantially higher CXCR4 occupancy.
The dual-application insight — stem cell mobilization for transplant AND tumor immune sensitization — came from the growing understanding that the same CXCL12/CXCR4 axis that anchors stem cells in bone marrow also creates immune-excluded tumor microenvironments. Blocking the receptor could serve both purposes, in entirely different patient populations.
Mechanism of Action
The CXCL12/CXCR4 Signaling Axis
CXCR4 is a G-protein coupled receptor expressed on hematopoietic stem cells, T cells, B cells, monocytes, and many cancer cell types. Its ligand, CXCL12 (stromal cell-derived factor 1, SDF-1), is constitutively expressed by bone marrow stromal cells, lymph node stroma, and the tumor microenvironment stroma.
The CXCL12/CXCR4 axis serves as a homing and retention system — it keeps CXCR4-positive cells in CXCL12-rich niches. In normal physiology, this retains hematopoietic stem cells in the bone marrow. In cancer, it retains immune cells outside the tumor and retains cancer cells in protective stromal niches.
PLAIN ENGLISH
Think of CXCR4 as a molecular leash and CXCL12 as the post it's tied to. Stem cells are leashed to bone marrow. Immune cells are leashed outside tumors. Motixafortide cuts the leash.
Application 1: Stem Cell Mobilization
When motixafortide blocks CXCR4 on hematopoietic stem cells, CXCL12 can no longer retain them in the bone marrow niche. CD34+ stem cells are rapidly released into peripheral blood — peaking 6–8 hours after subcutaneous injection — where they can be collected by apheresis for autologous transplantation.
This is directly competitive with plerixafor. Motixafortide's higher CXCR4 affinity translates to more efficient mobilization: in GENESIS, 92.5% of patients met the CD34+ cell collection target within two apheresis sessions, compared to historical plerixafor rates of approximately 70–80%.
Application 2: Tumor Immune Sensitization
In the tumor microenvironment, the same CXCR4 blockade has different consequences. By disrupting CXCL12-mediated immune exclusion, motixafortide enables CD8+ T cells and other immune effectors to infiltrate the tumor stroma. When combined with checkpoint inhibitors like pembrolizumab — which release the brakes on T-cell killing — this one-two punch can convert an immune-cold tumor to an immune-hot one.
The COMBAT trial biomarker data confirmed this mechanism in pancreatic cancer: post-treatment biopsies showed significantly increased CD8+ T-cell infiltration into tumors that had been previously immune-excluded.
PLAIN ENGLISH
In stem cell transplant, motixafortide frees stem cells from bone marrow so they can be collected. In cancer, it frees immune cells to enter tumors that were previously off-limits. Same mechanism, completely different medical applications.
Key Research Areas and Studies
GENESIS — Stem Cell Mobilization (Phase III)
The GENESIS trial (PMID 36455208) was the registrational study designed to support FDA approval of motixafortide for stem cell mobilization in multiple myeloma patients undergoing autologous transplantation.
Design: Randomized, double-blind, placebo-controlled Phase III. 122 patients with multiple myeloma eligible for autologous stem cell transplant. Motixafortide 1.25 mg/kg SC + G-CSF vs. placebo + G-CSF.
Primary endpoint: Proportion of patients collecting ≥6 × 10⁶ CD34+ cells/kg in ≤2 apheresis sessions.
Results: - Motixafortide arm: 92.5% met primary endpoint - Placebo arm: 26.2% met primary endpoint - p<0.0001 - No treatment-related serious adverse events in the motixafortide arm - Rapid mobilization onset: most patients achieved target in a single apheresis session
PLAIN ENGLISH
GENESIS tested whether motixafortide could get more stem cells out of bone marrow and into the blood than current standard methods. The answer was dramatically yes — more than 9 in 10 patients on motixafortide hit the target, versus roughly 1 in 4 on placebo. That's the kind of difference that changes clinical practice.
COMBAT — Pancreatic Cancer Immunotherapy (Phase 2a)
The COMBAT trial (Bockorny et al., 2020, PMID 32451495) explored motixafortide's immunomodulatory potential in metastatic pancreatic ductal adenocarcinoma — a cancer with a 5-year survival rate under 12% and notorious resistance to immunotherapy.
Design: Open-label Phase 2a. 37 patients with metastatic PDAC. Motixafortide 1.25 mg/kg SC daily × 5 days per cycle with pembrolizumab ± chemotherapy.
Results: - Combination cohort (motixafortide + pembrolizumab + chemotherapy): Disease control rate 77%, objective response rate 32% - Biomarker analysis: Increased CD8+ T-cell infiltration into tumors post-treatment — direct evidence of immune microenvironment remodeling - Safety consistent with known pembrolizumab and chemotherapy profiles — no unexpected toxicity from motixafortide
PLAIN ENGLISH
Pancreatic cancer is famously immune-resistant — checkpoint drugs that work in many other cancers fail here because immune cells can't reach the tumor. COMBAT showed that adding motixafortide helped immune cells infiltrate pancreatic tumors and the combination controlled disease in 77% of patients. That's early data, but it's exciting in a cancer where almost nothing works.
Phase 1b Dose-Escalation (Abraham et al., 2017, PMID 28750408)
The foundational Phase 1b trial established the safety and pharmacodynamic profile of motixafortide, demonstrating dose-dependent CD34+ mobilization with peak response at 6–8 hours post-injection and a favorable safety profile in healthy volunteers and multiple myeloma patients.
Claims vs. Evidence
| Claim | What the Evidence Shows | Verdict |
|---|---|---|
| “"Motixafortide mobilizes stem cells better than current standard"” | GENESIS Phase III (N=122): 92.5% vs. 26.2% met primary endpoint (p<0.0001). Note: comparison was against G-CSF + placebo, not G-CSF + plerixafor. | Supported |
| “"Motixafortide has higher CXCR4 affinity than plerixafor"” | In vitro binding data shows 20–40× higher affinity. No head-to-head clinical mobilization trial vs. plerixafor. | Mixed Evidence |
| “"Motixafortide enables immune infiltration of cold tumors"” | COMBAT biomarker data showed increased CD8+ T cells in pancreatic tumors. Proof of mechanism in a small Phase 2a. | Mixed Evidence |
| “"Motixafortide improves outcomes in pancreatic cancer"” | COMBAT Phase 2a (N=37): DCR 77%, ORR 32% in combination cohort. Encouraging but small, open-label, no control arm for the combination. | Mixed Evidence |
| “"Motixafortide is safer than plerixafor"” | No head-to-head safety comparison. GENESIS showed no treatment-related SAEs. Plerixafor also has a favorable safety profile. | Mixed Evidence |
| “"Motixafortide will replace plerixafor"” | GENESIS data is compelling but the study compared against placebo, not plerixafor. Regulatory approval and comparative data are needed. | Theoretical |
| “"CXCR4 blockade cures pancreatic cancer"” | COMBAT showed disease control, not cure. Pancreatic cancer remains lethal in the vast majority of patients. CXCR4 blockade is one component of combination strategies. | Unsupported |
| “"Motixafortide works for all immune-cold tumors"” | Tested only in pancreatic cancer to date. The CXCR4 mechanism is plausible across immune-excluded tumors, but clinical evidence is limited to one small trial in one tumor type. | Theoretical |
| “"Motixafortide is FDA-approved"” | Not approved. Phase III complete and NDA-enabling activities ongoing for stem cell mobilization. No approval date confirmed. | Unsupported |
| “"Peptide CXCR4 antagonists are superior to small molecules"” | Higher binding affinity does not automatically mean better clinical outcomes. The relevant comparison is clinical, not biochemical. | Theoretical |
| “"Motixafortide eliminates the need for G-CSF in mobilization"” | GENESIS used motixafortide + G-CSF. The combination was tested, not motixafortide alone. Single-agent mobilization data is limited. | Unsupported |
| “"COMBAT proves motixafortide makes immunotherapy work in all patients"” | COMBAT was a 37-patient open-label study. Responders were not universal. Larger controlled trials are needed to define which patients benefit. | Unsupported |
The Human Evidence Landscape
GENESIS Phase III (PMID 36455208)
Design: Randomized, double-blind, placebo-controlled Phase III Population: 122 multiple myeloma patients eligible for autologous stem cell transplant Intervention: Motixafortide 1.25 mg/kg SC + G-CSF vs. placebo + G-CSF Key finding: 92.5% vs. 26.2% achieved ≥6 × 10⁶ CD34+ cells/kg in ≤2 apheresis sessions (p<0.0001). No treatment-related SAEs. Limitations: Compared against G-CSF + placebo, not G-CSF + plerixafor (the current approved standard). This limits the ability to claim superiority over the existing approved therapy. Regulatory pathway requires demonstrating advantage over or non-inferiority to the active comparator.
COMBAT Phase 2a (Bockorny et al., 2020, PMID 32451495)
Design: Open-label Phase 2a Population: 37 patients with metastatic pancreatic ductal adenocarcinoma Intervention: Motixafortide 1.25 mg/kg SC daily × 5 days/cycle + pembrolizumab ± chemotherapy Key finding: Combination cohort DCR 77%, ORR 32%. Biomarker evidence of increased CD8+ T-cell infiltration. Limitations: Small sample size (37 patients). Open-label with no control arm for the combination cohort. Cannot distinguish motixafortide's contribution from chemotherapy + pembrolizumab alone. Phase 2a — hypothesis-generating, not definitive.
Phase 1b (Abraham et al., 2017, PMID 28750408)
Design: Dose-escalation Phase 1b Population: ~40 healthy volunteers and multiple myeloma patients Key finding: Dose-dependent CD34+ mobilization. Peak at 6–8 hours. Well-tolerated. Limitations: Early-phase, small, not designed for efficacy.
Safety, Risks, and Limitations
Clinical Safety Profile
Motixafortide's safety profile across GENESIS and COMBAT is favorable, with no unexpected toxicity signals:
Injection site reactions (most common): Erythema, pain, and warmth at the subcutaneous injection site. Typically mild and self-resolving.
GI effects: Nausea and diarrhea, generally mild to moderate.
Systemic: Headache, dizziness, and fatigue reported in a minority of patients.
Transient leukocytosis: An expected pharmacological effect of CXCR4 blockade — when you release cells from bone marrow, white blood cell counts rise temporarily. This is not a safety concern; it's the mechanism working.
Hematologic monitoring: Because CXCR4 blockade releases hematopoietic cells, blood counts should be monitored during treatment.
Immunotherapy Combination Safety
In COMBAT, immune-related adverse events were consistent with pembrolizumab's known safety profile. No unexpected toxicity was attributed to the motixafortide component. However, the combination of CXCR4 blockade with checkpoint inhibition raises a theoretical concern: if motixafortide enhances immune cell infiltration into tumors, it could also enhance autoimmune side effects. This requires monitoring in larger trials.
PLAIN ENGLISH
In clinical trials so far, motixafortide has been well-tolerated. The most common side effects are injection-site reactions and mild stomach issues. The main theoretical concern is that by boosting immune activity, it could also increase immune-related side effects when combined with immunotherapy drugs — something larger trials will need to watch for.
Legal and Regulatory Status
Investigational Drug
Motixafortide is not FDA-approved. It is an investigational compound developed by BioLineRx Ltd. (NASDAQ: BLRX).
Regulatory Pathway
- Stem cell mobilization: GENESIS Phase III met its primary endpoint. BioLineRx has indicated NDA-enabling activities are ongoing. The regulatory path depends on FDA guidance regarding the comparator issue — GENESIS compared against placebo, not the approved active comparator (plerixafor).
- Oncology (immuno-oncology): COMBAT Phase 2a is hypothesis-generating. Additional controlled trials would be required before any oncology regulatory submission.
Access
Available only through clinical trials and any expanded access programs that BioLineRx may offer. Not available from compounding pharmacies or peptide vendors.
Research Protocols and Formulation Considerations
Formulation
Motixafortide is supplied as an injectable solution for subcutaneous administration. Unlike the somatostatin analogs in this cluster, it does not require specialized delivery devices, radioactive handling, or depot formulations.
Storage
Details per investigational drug protocols — stored refrigerated, standard peptide handling.
Combination Protocols
The oncology development program uses motixafortide in combination with other agents: - Stem cell mobilization: Motixafortide + G-CSF (GENESIS protocol) - Immuno-oncology: Motixafortide + pembrolizumab ± chemotherapy (COMBAT protocol)
Single-agent motixafortide is not expected to have meaningful antitumor activity — its value is as an immune enabler in combination.
Dosing in Published Research
The following table summarizes dosing protocols for Motixafortide as reported in published clinical and preclinical research. These reflect study designs, not treatment recommendations.
Clinical Trial Dosing
Stem Cell Mobilization (GENESIS Protocol):
| Parameter | Value |
|---|---|
| Dose | 1.25 mg/kg SC |
| Schedule | Single dose on the day before apheresis |
| Combination | Given with G-CSF (standard mobilization regimen) |
| Onset | Peak CD34+ mobilization at 6–8 hours post-injection |
| Duration | Single dose typically sufficient for target cell collection |
Pancreatic Cancer Immunotherapy (COMBAT Protocol):
| Parameter | Value |
|---|---|
| Dose | 1.25 mg/kg SC daily × 5 days per treatment cycle |
| Combination | Given with pembrolizumab (200 mg IV q3w) ± chemotherapy |
| Setting | Oncology infusion center |
| Monitoring | Regular imaging + biomarker assessment |
PLAIN ENGLISH
For stem cell transplant preparation, motixafortide is a single injection the day before collection. For cancer treatment, it's daily injections for five days per cycle, alongside other cancer drugs.
Combination Stacks
COMMUNITY-SOURCED INFORMATION
The dosing information below is drawn from community reports, forums, and anecdotal sources — not clinical trials. It reflects what people report using, not what has been validated by research. This is not medical advice.
Research into Motixafortide combination protocols is limited. The stacking practices described below are drawn from community reports and have not been validated in controlled studies.
If you are considering combining Motixafortide with other compounds, consult a qualified healthcare provider. Interactions between peptides and other substances are poorly characterized in the literature.
| Compound | Type | Evidence Tier | Verdict | Primary Mechanism | Target/Receptor | Landmark Trial | Human Data | FDA Status | WADA Status | Key Limitation |
|---|---|---|---|---|---|---|---|---|---|---|
| Octreotide | Cyclic octapeptide SSA (8 aa, disulfide) | Tier 1 — Approved Drug | Strong Foundation | SSTR2/5 agonist → antisecretory + antiproliferative | SSTR2, SSTR5 | PROMID (N=85, TTP HR 0.34) | Phase III RCT; 30+ years clinical use | Approved 1988 (acromegaly, carcinoid, GEP-NETs) | Not prohibited | Gallstones (15–30%); glucose metabolism effects |
| Lanreotide | Cyclic octapeptide SSA (8 aa, disulfide) | Tier 1 — Approved Drug | Strong Foundation | SSTR2/3/5 agonist → antiproliferative in nonfunctioning NETs | SSTR2, SSTR3, SSTR5 | CLARINET (N=204, PFS HR 0.47) | Phase III RCT; 15+ years post-approval | Approved 2007 (acromegaly); 2014 (GEP-NETs) | Not prohibited | Same class as octreotide; gallstones; glucose effects |
| Lutathera | Radiolabeled peptide (¹⁷⁷Lu-DOTATATE) | Tier 1 — Approved Drug | Strong Foundation | SSTR2-targeted PRRT → intracellular beta-radiation → DNA damage | SSTR2 | NETTER-1 (N=229, PFS HR 0.21) | Phase III RCT + 504-pt registry | Approved January 2018 (SSTR+ GEP-NETs) | Not prohibited | Myelosuppression; MDS/AML risk (~2%); requires nuclear medicine facility |
| Motixafortide | Cyclic peptide (14 aa) | Tier 2 — Clinical Trials | Reasonable Bet | CXCR4 antagonist → stem cell mobilization + tumor immune sensitization | CXCR4 | GENESIS (N=122, 92.5% vs. 26.2% mobilization) | Phase III + Phase 2a (N=199 total) | Not approved (Phase 3 complete) | Not prohibited | No FDA approval yet; competes with approved plerixafor |
| Melflufen | Peptide-drug conjugate (dipeptide-melphalan) | Tier 2 — Clinical Trials | Thin Ice | Aminopeptidase-activated intracellular melphalan release → DNA crosslinking | Aminopeptidase N (CD13) | OCEAN (N=495, PFS HR 0.79 but OS HR 1.104) | Phase III RCT (N=652 total) | Approved Feb 2021; WITHDRAWN Feb 2024 | Not prohibited | Worse OS than comparator; severe myelosuppression; market withdrawal |
| Cilengitide | Cyclic RGD pentapeptide (5 aa) | Tier 2 — Clinical Trials | Thin Ice | αvβ3/αvβ5 integrin antagonist → antiangiogenic | αvβ3, αvβ5 integrins | CENTRIC (N=545, OS HR 1.02) | Phase III RCT (N=891 total) | Not approved; development discontinued | Not prohibited | Definitive Phase III failure (HR 1.02); development abandoned |
style="color:#0F4C5C;font-size:28px;font-weight:700;margin:48px 0 16px 0;line-height:1.2">Frequently Asked Questions
What is motixafortide and what does it do?
Is motixafortide FDA-approved?
What is the GENESIS trial?
What is the COMBAT trial?
How does motixafortide compare to plerixafor (Mozobil)?
Can motixafortide cure pancreatic cancer?
What are the side effects of motixafortide?
Is motixafortide available for purchase?
What is the CXCR4/CXCL12 axis?
Could motixafortide work for cancers other than pancreatic?
Why is a peptide CXCR4 antagonist potentially better than a small molecule?
What is the next step for motixafortide's development?
Summary of Key Findings
Motixafortide is a cyclic peptide CXCR4 antagonist with positive Phase III data in stem cell mobilization and intriguing Phase 2a data suggesting it can convert immune-excluded tumors into immune-infiltrated ones. The GENESIS trial's 92.5% vs. 26.2% result is one of the most dramatic efficacy differences in the stem cell transplant space.
The COMBAT data in pancreatic cancer — one of the most immunotherapy-resistant cancers — provides direct biomarker evidence that CXCR4 blockade enables immune cell infiltration. If this mechanism holds in larger controlled trials, it could have implications far beyond pancreatic cancer.
Motixafortide occupies a unique position in the Cancer and Oncology cluster: while the somatostatin analogs target tumor cells directly through SSTR2, motixafortide remodels the battlefield — clearing the path for the immune system to do the killing.
PLAIN ENGLISH
Motixafortide is an experimental peptide that blocks a molecular signal keeping stem cells in bone marrow and immune cells out of tumors. It proved it can release stem cells in a large clinical trial, and showed early evidence of helping immune cells infiltrate one of the hardest-to-treat cancers. It's not approved yet, but the data so far is genuinely promising.
Verdict Recapitulation
Motixafortide has cleared the clinical trial hurdle — a positive Phase III in stem cell mobilization and mechanistic proof-of-concept in immuno-oncology. The remaining questions are regulatory (will the FDA accept a placebo-controlled trial without an active comparator?) and clinical (will the COMBAT immunotherapy results hold in larger, controlled studies?). The science is sound. The early data is positive. The compound merits cautious optimism, not certainty.
For readers considering Motixafortide, the evidence above represents the current state of knowledge. As always, consult a qualified healthcare provider before making any decisions about peptide use.
Where to Source Motixafortide
Further Reading and Resources
If you want to go deeper on Motixafortide, the evidence landscape for cancer & oncology peptides, or the methodology behind how we evaluate this research, these are the places worth your time.
ON PEPTIDINGS
- Cancer & Oncology Research Hub — Overview of all compounds in this cluster
- Reconstitution Guide — How to properly prepare injectable peptides
- Storage and Handling Guide — Proper storage to maintain peptide stability
- About Peptidings — Our editorial methodology and evidence framework
EXTERNAL RESOURCES
- PubMed: Motixafortide — All indexed publications
- ClinicalTrials.gov — Active and completed trials
Selected References and Key Studies
- BioLineRx. (2022). "GENESIS Phase 3 trial of motixafortide for stem cell mobilization in multiple myeloma." Published results. PMID 36455208
- Bockorny B, Semenisty V, Macarulla T, et al. (2020). "BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial." Nature Medicine, 26(6), 878–885. PMID 32451495
- Abraham M, Pereg Y, Galsky MD, et al. (2017). "Safety and efficacy of BL-8040 (motixafortide), a CXCR4 antagonist, in combination with G-CSF for CD34+ cell mobilization: Phase 1b study." Blood, 130(Suppl 1), 4479. PMID 28750408
- Domanska UM, Kruizinga RC, Nagengast WB, et al. (2013). "A review on CXCR4/CXCL12 axis in oncology: no place to hide." European Journal of Cancer, 49(1), 219–230. PMID 22683307
- DiPersio JF, Stadtmauer EA, Nademanee A, et al. (2009). "Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation." Blood, 113(23), 5720–5726. PMID 19363221
- Fearon DT. (2014). "The carcinoma-associated fibroblast expressing fibroblast activation protein and escape from immune surveillance." Cancer Immunology Research, 2(3), 187–193. PMID 24778315
DISCLAIMER
Motixafortide is not approved by the FDA for any indication in the United States. The information presented in this article is for educational and research purposes only. Nothing in this article constitutes medical advice, and no material here is intended to diagnose, treat, cure, or prevent any disease or health condition.
Consult a qualified healthcare provider before making any decisions about peptide use. Report adverse events to the FDA via MedWatch.
For the full Peptidings editorial methodology and evidence framework, visit our About page and Evidence Framework pages.
Article last reviewed: April 11, 2026. Next scheduled review: October 08, 2026.